Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock Now Rated “Hold” by Sell-Side Analysts

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been given a consensus recommendation of “Hold” by the five analysts that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $8.18.

RXRX has been the topic of a number of research analyst reports. Morgan Stanley set a $5.90 price objective on shares of Recursion Pharmaceuticals in a research report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Thursday. Wall Street Zen raised shares of Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a research note on Monday.

Recursion Pharmaceuticals Stock Up 4.3%

Shares of NASDAQ:RXRX opened at $3.61 on Tuesday. The stock’s 50-day moving average is $3.64 and its 200 day moving average is $3.42. The company has a market cap of $1.93 billion, a PE ratio of -3.47 and a beta of 1.04. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.03 and a quick ratio of 5.03. Recursion Pharmaceuticals has a 1 year low of $2.77 and a 1 year high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%. The business had revenue of $7.67 million during the quarter, compared to the consensus estimate of $10.97 million. During the same quarter in the prior year, the business posted ($0.41) earnings per share. Sell-side analysts anticipate that Recursion Pharmaceuticals will post -0.94 EPS for the current year.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, CEO Najat Khan sold 22,408 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $3.52, for a total transaction of $78,876.16. Following the sale, the chief executive officer directly owned 2,072,890 shares of the company’s stock, valued at approximately $7,296,572.80. The trade was a 1.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $4.84, for a total value of $242,000.00. Following the transaction, the director owned 6,108,287 shares in the company, valued at $29,564,109.08. This trade represents a 0.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 157,408 shares of company stock valued at $643,576 over the last three months. Corporate insiders own 6.65% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Abel Hall LLC increased its stake in shares of Recursion Pharmaceuticals by 73.1% in the 3rd quarter. Abel Hall LLC now owns 22,856 shares of the company’s stock worth $94,000 after acquiring an additional 9,651 shares in the last quarter. TD Waterhouse Canada Inc. lifted its position in Recursion Pharmaceuticals by 193.2% during the 3rd quarter. TD Waterhouse Canada Inc. now owns 59,613 shares of the company’s stock valued at $243,000 after acquiring an additional 39,282 shares during the period. Green Alpha Advisors LLC lifted its position in Recursion Pharmaceuticals by 62.3% during the 3rd quarter. Green Alpha Advisors LLC now owns 239,404 shares of the company’s stock valued at $989,000 after acquiring an additional 91,860 shares during the period. Whalen Wealth Management Inc. bought a new stake in Recursion Pharmaceuticals during the third quarter worth about $199,000. Finally, MCF Advisors LLC bought a new stake in Recursion Pharmaceuticals during the second quarter worth about $27,000. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc is a clinical-stage biotechnology company that uses biology, chemistry, automation and machine learning to discover and develop new medicines. The company’s technology platform is designed to generate and analyze large volumes of biological and chemical data, helping researchers identify potential drug candidates and better understand disease mechanisms.

Recursion has focused its research and development activities on areas including oncology, rare diseases and neuroscience.